Premium
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium
Author(s) -
Harrison Douglas J.,
Gill Jonathan D.,
Roth Michael E.,
Zhang Wendong,
Teicher Beverly,
Erickson Stephen,
Gatto Greg,
Kurmasheva Raushan T.,
Houghton Peter J.,
Smith Malcolm A.,
Kolb Edward Anders,
Gorlick Richard
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28222
Subject(s) - regorafenib , medicine , sorafenib , in vivo , rhabdomyosarcoma , pdgfrb , kinase , pharmacology , sarcoma , preclinical testing , cancer research , oncology , pathology , biology , cancer , colorectal cancer , biochemistry , microbiology and biotechnology , hepatocellular carcinoma , gene , medical physics
Background Regorafenib is a small molecule multikinase inhibitor that inhibits multiple kinases including BRAF, KIT, PDGFRB, RAF, RET, and VEGFR1‐3. Procedures The in vivo anticancer effects of regorafenib were assessed in a panel of six osteosarcoma models, three rhabdomyosarcoma models, and one Ewing sarcoma model. Results Regorafenib induced modest inhibition of tumor growth in the models evaluated. Conclusion The overall pattern of response to regorafenib appears similar to that of the kinase inhibitor sorafenib, with pronounced slowing of tumor growth in some models, limited to the period of agent administration, being the primary treatment effect.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom